Key Points A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years. Investors appear to be worried about what lies ahead for the business. 10 stocks we like better than Pfizer › Healthcare giant Pfizer (NYSE: PFE) has been offering a high yield for some time. But that hasn't been enough to get investors to buy up the stock. You can see that in its sluggish share price, and also in the fact ...

Group 1: Smith & Wesson Brands - Smith & Wesson Brands is currently trading at $8.66, with a 52-week range of $8.38 to $16.85 and a dividend yield of 6.00% [2] - The company faces significant headwinds, including tariffs and revenue deleveraging, which have negatively impacted margins and led to insufficient income to cover the dividend [2][3] - The payout ratio is projected to exceed 150% by the end of fiscal 2025, raising concerns about the sustainability of the dividend [2][3] - Analysts have a consensus rating of Moderate Buy, but sentiment is declining, and the price target is falling, indicating potential further downside risk [4] Group 2: SunCoke Energy - SunCoke Energy is trading at $8.18, with a 52-week range of $7.47 to $12.82 and a dividend yield of 5.86% [6] - The company has headwinds from weaker coal prices; however, its dividend payment is considered safe due to long-term contracts that guarantee cash flow [6][7] - The payout ratio is expected to be around 70% in 2025, which is sustainable for the business [6] - A recent acquisition of Phoenix Global is anticipated to positively impact revenue and profitability, diversifying SunCoke's business [7] - MarketBeat tracks one analyst rating this stock as a Buy, with a price target over 65% above current trading levels, supported by strong institutional ownership [8] Group 3: Tronox Holdings - Tronox Holdings is trading at $5.67, with a 52-week range of $4.35 to $17.45 and a dividend yield of 8.82% [10] - The company reported a net loss for the previous fiscal year, but analysts believe it is at a turning point due to shifts in demand for TiO2 pigments [10][12] - The consensus rating among eight analysts is Moderate Buy, indicating potential for a 50% upside, with recent upgrades from JPMorgan raising the price target to $7 [11] - Tronox's balance sheet is strong enough to sustain the dividend until business conditions improve, with expectations of positive earnings by the end of the fiscal year [12]

Core Viewpoint - UnitedHealth Group's stock has experienced a significant decline of over 40% in 2025, yet it remains one of the largest healthcare companies with a market cap exceeding $270 billion [1] Financial Performance - The stock's dividend yield has risen to 2.8%, surpassing the S&P 500 average of 1.3%, which raises concerns about the potential risk to the dividend [2] - UnitedHealth's current payout ratio is approximately 35%, indicating a healthy buffer for dividend payments [5] - Over the last 12 months, UnitedHealth generated a free cash flow of $24.9 billion while paying out $7.7 billion in dividends, suggesting the dividend is secure as long as cash flow remains strong [6] Future Concerns - There are significant risks related to a criminal investigation into the company's billing practices and potential Medicare fraud, which could impact future financial stability [9] - The U.S. government's potential cuts to healthcare spending may pose additional challenges to the company's growth prospects [9] - Recent news of CEO Andrew Witty's resignation has further contributed to investor uncertainty [10] Investment Outlook - Despite current risks, the dividend appears safe, and the company plays a crucial role in providing healthcare coverage to millions [11] - The stock is trading at less than 13 times its trailing earnings, which is significantly lower than the S&P 500 average of just under 24, indicating potential long-term value for investors willing to endure short-term volatility [12][13]